Literature DB >> 9235910

Activation of RNase L by 2',5'-oligoadenylates. Kinetic characterization.

S S Carroll1, J L Cole, T Viscount, J Geib, J Gehman, L C Kuo.   

Abstract

Ribonuclease L (RNase L), the 2',5'-oligoadenylate-dependent ribonuclease, is one of the cellular antiviral systems with enhanced activity in the presence of interferon. A reaction scheme has been developed to model the sequence of steps necessary for the activation of RNase L (Cole, J. L., Carroll, S. S., Blue, E. S., Viscount, T., and Kuo, L. C. (1997) J. Biol. Chem. 272, 19187-19192). The model comprises three sequential binding steps: the binding of activator to enzyme monomer, the subsequent dimerization of the activated monomer to form the active enzyme dimer, followed by the binding of substrate prior to catalysis. The model is used to evaluate the activation of RNase L by several synthetic analogs of the native activator. The 5'-phosphate of the activator has been determined to be an important structural determinant for the efficient activation of RNase L, and its loss caused a loss of activator affinity of 2-3 orders of magnitude. The length of activator is not an important determinant of activator potency for the activator analogs examined. The specific activity of the enzyme under conditions of saturation of activator binding and complete dimerization of the activated monomers varies only by about a factor of 3 for the activators examined, indicating that once dimerized in the presence of any of these activators, the enzyme exhibits a similar catalytic activity.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9235910     DOI: 10.1074/jbc.272.31.19193

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  Inhibition of RNase L and RNA-dependent protein kinase (PKR) by sunitinib impairs antiviral innate immunity.

Authors:  Babal Kant Jha; Irina Polyakova; Patricia Kessler; Beihua Dong; Benjamin Dickerman; Ganes C Sen; Robert H Silverman
Journal:  J Biol Chem       Date:  2011-06-02       Impact factor: 5.157

2.  Analysis of heterogeneous interactions.

Authors:  James L Cole
Journal:  Methods Enzymol       Date:  2004       Impact factor: 1.600

Review 3.  New insights into the role of RNase L in innate immunity.

Authors:  Arindam Chakrabarti; Babal Kant Jha; Robert H Silverman
Journal:  J Interferon Cytokine Res       Date:  2010-12-29       Impact factor: 2.607

Review 4.  A scientific journey through the 2-5A/RNase L system.

Authors:  Robert H Silverman
Journal:  Cytokine Growth Factor Rev       Date:  2007-07-27       Impact factor: 7.638

5.  Type III CRISPR-Cas systems produce cyclic oligoadenylate second messengers.

Authors:  Ole Niewoehner; Carmela Garcia-Doval; Jakob T Rostøl; Christian Berk; Frank Schwede; Laurent Bigler; Jonathan Hall; Luciano A Marraffini; Martin Jinek
Journal:  Nature       Date:  2017-07-19       Impact factor: 49.962

6.  Activation and evasion of the antiviral 2'-5' oligoadenylate synthetase/ribonuclease L pathway by hepatitis C virus mRNA.

Authors:  Jian-Qiu Han; David J Barton
Journal:  RNA       Date:  2002-04       Impact factor: 4.942

7.  A viral RNA competitively inhibits the antiviral endoribonuclease domain of RNase L.

Authors:  Hannah L Townsend; Babal K Jha; Jian-Qiu Han; N Karl Maluf; Robert H Silverman; David J Barton
Journal:  RNA       Date:  2008-04-21       Impact factor: 4.942

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.